A phase II safety and tolerability study of bevacizumab when added to single-agent chemotherapy to treat patient with breast cancer metastatic to brain

Trial Profile

A phase II safety and tolerability study of bevacizumab when added to single-agent chemotherapy to treat patient with breast cancer metastatic to brain

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Docetaxel; Gemcitabine; Irinotecan; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Oct 2011 Planned end date changed from 1 May 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 03 Feb 2010 Planned end date changed from 1 May 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top